Furthermore, the application of a pharmaceutical-cosmetic acceptability formulation design to provide stratum corneum moderate moisturizing and barrier repair for ingredients, inhibit the skin CYP-mediated metabolism for the CYP substrate active compounds, and improve treatment adherence should be considered for inflammatory skin diseases treatment. The gene discussed is PPIG; the disease is inflammatory skin disease.